Table S1. Standardized questionnaire for collecting data on statin followed up

SECTION 3: CURRENT MEDCIATIONS (if patient alive)

3.25 Statin ☐ Yes ☐ No

If yes, trade name is:_____

Dose _____mg/day

If no, reason is: (select one)

☐ Not prescribed

☐ Patient refused

Reason is: (select one)

☐ Cost

☐ Other

☐ Intolerance

☐ Unknown

☐ Other(*specify*)_____

1

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Table S2: Dosage of different type of statins with equivalent efficacy on lipid measures

Equivalent dosages of statins (mg)					Efficacy in mean reduction of lipid measures (%)			
Atorva-statin	Simva-statin	Lova-statin	Prava-statin	Fluva-statin	TC	LDL-C	HDL-C	TG
-	10	20	20	40	-22	-27	4~8	-(10~15)
10	20	40	40	80	-27	-34	4~8	-(10~20)
20	40	80			-32	-41	4~8	-(15~25)
40	80				-37	-48	4~8	-(20~30)
80					-42	-55	4~8	-(25~35)

Source: P Jones 1, S Kafonek, I Laurora, D Hunninghake. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) .Am J Cardiol, 1998 Mar 1;81(5):582-7. doi: 10.1016/s0002-9149(97)00965-x. (Reference No. 24 in the main text).

2

Table S3. Comparison of characteristics of patients with ACS between those followed-up and those lost to follow-up

Characteristics	Followed-up (n=10337)		Lost to follow-up (n=2742)		P values
	n	%	n	%	
Year of enrolment					
2007	383	3.7	161	5.9	<0.001
2008	3309	32.0	874	31.9	
2009	4982	48.2	1170	42.7	
2010	1663	16.1	537	19.6	
Subtype of ACS					
STEMI*	3918	37.9	1284	46.8	<0.001
NSTEMI*	1394	13.5	409	14.9	
UA*	5025	48.6	1049	38.3	
Clinical pathway intervention	7908	76.5	2077	75.8	0.409
Sex (Female)	3074	29.7	791	28.9	0.364
Age>=65	4934	47.7	1381	50.4	0.014
Education>=high school	3786	36.6	1028	37.5	0.404
Unemployed	5033	48.7	1494	54.5	<0.001
With medical insurance	8678	83.9	2172	79.2	<0.001
Current smoker	3192	30.9	906	33.0	0.030
History of disease					
Dyslipidemia	1359	13.1	315	11.5	0.021
Diabetes	2086	20.2	529	19.3	0.302
Hypertension	7184	69.5	1798	65.6	<0.001
Heart Failure	562	5.4	160	5.8	0.417
Stroke	944	9.1	278	10.1	0.107
In-hospital MACE	191	1.8	283	10.3	<0.001
In-hospital PCI/CABG	5113	49.5	1471	53.7	<0.001
LDL-c level in hospital					
Not measuring	909	8.8	299	10.9	0.003
<160mg/dl	8850	85.6	2287	83.4	
>=160mg/dl	578	5.6	156	5.7	
Prior statin use	1467	14.2	381	13.9	0.692
Dose of statin at discharge					
1-9 mg/d	1904	18.4	672	24.5	<0.001
10-19 mg/d	3196	30.9	500	18.2	
>=20 mg/d	5237	50.7	1570	57.3	
Type of statin at discharge					
Atorvastatin	5785	56.0	1712	62.4	<0.001
Simvastatin	2690	26.0	509	18.6	
Rosuvastatin	502	4.9	40	1.5	
Pravastatin	502	4.9	163	5.9	

3

Fluvastatin	578	5.6	166	6.1	
Other statin	280	2.7	152	5.5	
Co-treatments at discharge					
Aspirin	10030	97.0	2645	96.5	0.127
Clopidogrel	8404	81.3	2416	88.1	<0.001
β-blocker	8155	78.9	2076	75.7	<0.001
ACEI/ARB*	8096	78.3	2161	78.8	0.579

* STEMI was ST-segment elevation myocardial infarction; NSTEMI was Non-ST-segment

elevation myocardial infarction; UA was unstable angina; ACEI was Angiotensin converting

enzyme inhibitor; ARB was Angiotensin Receptor Blocker